Tolterodine has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rivastigmine, Rivastigmine Tartrate, Clarithromycin. Patients taking Tolterodine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Contraindicated
- 2
- Major
- 4
- Moderate
- 7
Contraindicated (2)
- Tolterodine + Rivastigmine— Rivastigmine may interfere with anticholinergic activity. Concomitant use not recommended unless clinically necessary.
- Tolterodine + Rivastigmine Tartrate— Rivastigmine may interfere with anticholinergic activity of tolterodine. Concomitant use not recommended unless clinical…
Major (4)
- Tolterodine + Clarithromycin— Potent CYP3A4 inhibitor that may increase tolterodine systemic exposure. Dose reduction to 2 mg once daily recommended.
- Tolterodine + Itraconazole— Potent CYP3A4 inhibitor that may increase tolterodine systemic exposure. Dose reduction to 2 mg once daily recommended.
- Tolterodine + Ketoconazole— Potent CYP3A4 inhibitor increases tolterodine Cmax and AUC 2- to 2.5-fold in poor metabolizers. Dose reduction to 2 mg o…
- Tolterodine + Ritonavir— Potent CYP3A4 inhibitor that may increase tolterodine systemic exposure. Dose reduction to 2 mg once daily recommended.
Moderate (7)
- Tolterodine + Desvenlafaxine— Desvenlafaxine increases tolterodine levels. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment nee…
- Tolterodine + Desvenlafaxine Er— Desvenlafaxine increases tolterodine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment n…
- Tolterodine + Desvenlafaxine Succinate— Concomitant use increases exposure (Cmax and AUC). Reduce dose by up to one-half if co-administered with 400 mg desvenla…
- Tolterodine + Fluoxetine— Potent CYP2D6 inhibitor that significantly inhibited tolterodine metabolism, resulting in 4.8-fold increase in tolterodi…
- Tolterodine + Other Anticholinergic Agents— Concomitant use may increase frequency and/or severity of dry mouth, constipation, blurred vision, somnolence, and other…
- Tolterodine + Paroxetine— Increased tolterodine exposure may occur; dosage adjustment may be needed.
- Tolterodine + Paroxetine Hydrochloride— Increased exposure of CYP2D6 substrate; decrease dosage if needed.